On September 9, 2016, the Board of Directors of HH Biotechnology Holdings Company announced that Jiang Peng resigned from the Board of Directors on that date. As a result there were two vacancies on the Board. Consequently, on September 9, 2016, the Board elected Ying Huang and Sheng Jiang as directors of the company to serve until the next annual meeting of stockholders and until their respective successors are duly elected and qualified.

Sheng Jiang is the son of Frank Jiang, who is a director and principal stockholder of the company. As a result of these changes Frank Jiang's service as Chief Executive Officer and Chief Financial Officer ended on September 9, 2016. Frank Jiang continues to serve as a director and Chairman of the Board.

The Named Executive Officers of the company are Sheng Jiang, Chief Executive Officer, and Lirong Wang, Chief Financial Officer.